Lisdexamfetamine: English spelling of lisdexamfetamine (prodrug of dexamfetamine)
Lisdexamfetamine is the English spelling of lisdexamfetamine (also lisdexamphetamine). Both forms designate the same active substance, a prodrug that is enzymatically converted in the body to the pharmacologically active dexamfetamine. The distinction in spelling derives from international nomenclature: lisdexamfetamine is the form used according to BAN (British Approved Names) and INN (International Nonproprietary Name), while lisdexamfetamine is customary in German-speaking countries. A detailed German pillar page can be found at /wirkstoff/lisdexamfetamin.
In Europe, lisdexamfetamine is approved under the brand name Elvanse (Vyvanse in the USA) since 2013 for the treatment of attention deficit hyperactivity disorder (ADHD) in children from 6 years of age, and in Germany also for adults with persistent ADHD that has shown insufficient response to methylphenidate. In the USA, there is an additional approval for moderate to severe binge eating disorder in adults. Due to its potential for abuse, lisdexamfetamine in Germany is subject to the Controlled Substances Act (BtM prescription).
Mechanism of Action
Lisdexamfetamine is a conjugate of L-lysine and d-amphetamine. As a prodrug, it is itself pharmacologically inactive. Only in the bloodstream is it enzymatically hydrolyzed (predominantly in red blood cells) and gradually releases dexamfetamine. This delayed release creates a very consistent drug level over 12 to 14 hours and reduces the risk of peak-induced abuse potential.
Dexamfetamine itself works through two mechanisms. First, it releases noradrenaline and dopamine from presynaptic storage vesicles via reverse transport at the vesicular monoamine transporter VMAT2. Second, it inhibits the reuptake of these neurotransmitters via DAT and NET. The combined effect leads to a significant increase in dopaminergic and noradrenergic signal transmission in the prefrontal cortex, which improves attention, concentration, and impulse control.
Due to the prodrug properties and erythrocytic activation, lisdexamfetamine cannot be bypassed by snorting or injection, making it less prone to abuse than immediate-release dexamfetamine. This property contributed to its development as an approved ADHD medication.
Indications
- ADHD in children from 6 years of age: as part of a comprehensive therapeutic approach when non-pharmacological measures alone are insufficient, after insufficient response to methylphenidate
- ADHD in adolescents and adults: with persistent symptoms after comprehensive diagnostic evaluation
- Binge eating disorder, moderate to severe: approved in the USA, off-label in Europe
- Narcolepsy and hypersomnia: historical and off-label use, superseded by other substances
Dosage and Administration
ADHD in adults and adolescents: initial dose 30 mg in the morning, titration in 20 mg increments at weekly intervals until effective dose (typically 50 to 70 mg/day, maximum 70 mg). Children from 6 years of age: initial dose 20 mg in the morning, titration analogous.
Administration: once daily in the morning, either as a capsule or by dissolving in water, yogurt, or orange juice. Late administration after noon may lead to sleep disturbances. May be taken with or without food; high-fat meals do not significantly delay absorption.
Renal impairment: with eGFR 15 to 30 ml/min maximum dose 50 mg, with eGFR below 15 ml/min maximum dose 30 mg. Discontinuation: gradual tapering is not mandatory but is frequently recommended in practice to mitigate rebound symptoms.
Side Effects
Very common: decreased appetite, weight loss, sleep disturbances, headache, dry mouth, tachycardia, increased blood pressure, irritability, mood swings.
Common: nausea, vomiting, abdominal pain, tic exacerbation in tic disorders, anxiety, depressive mood.
Serious, rare: psychosis or mania, particularly in patients with pre-existing psychiatric disorders; ischemic events, myocardial infarction, stroke (especially in those with cardiovascular risk factors); aggression; suicidality in adolescents; ischemic skin changes particularly on fingers and toes suggesting Raynaud's phenomenon.
Important: Patients with cardiovascular pre-existing conditions, pre-existing psychosis, glaucoma, marked anxiety disorders, or substance dependence should generally not receive lisdexamfetamine.
Drug Interactions
- MAO inhibitors (tranylcypromine, moclobemide, linezolid): hypertensive crisis possible, combination contraindicated; at least 14 days washout
- Serotonergic agents (SSRIs, SNRIs, triptans, tramadol): serotonin syndrome risk, caution and patient education advised
- Sympathomimetics (pseudoephedrine, phenylephrine): additive cardiovascular effects
- Antihypertensives: reduced efficacy, blood pressure monitoring required
- Gastric acid-modifying agents (ascorbic acid, sodium bicarbonate): altered absorption due to pH shift
- Tricyclic antidepressants: potentiated sympathomimetic effects
Special Precautions
Pregnancy and breastfeeding: contraindicated as amphetamines cross the placenta and breast milk and can cause cardiovascular and neurological effects in the child.
Controlled Substance Status: Lisdexamfetamine in Germany is subject to the Controlled Substances Act and is prescribed on a BtM prescription. The prescription is limited to 30 days of supply, and medical therapy monitoring is mandatory.
Cardiovascular evaluation before therapy: ECG, medical history of cardiovascular disease, family history of sudden cardiac death, blood pressure measurement. Consult cardiology if abnormal findings.
Growth in children: regular monitoring of height and weight, as lisdexamfetamine may slow growth; if significant delays occur, consider therapy adjustment.
Therapy breaks: on weekends, school holidays, or vacation, therapy may be paused by individual agreement to improve growth, appetite, and overall well-being. This practice is controversial and should be coordinated with the treating physician.
You Might Also Be Interested In
- Lisdexamfetamine, detailed German pillar page
- Methylphenidate, classic ADHD stimulant
- Dexamfetamine, the active metabolite
- Atomoxetine, non-stimulant for ADHD
- Guanfacine, alpha-2 agonist for ADHD
Frequently Asked Questions
Is lisdexamfetamine the same as lisdexamfetamin?
Yes. Lisdexamfetamine is the English spelling (BAN/INN), lisdexamfetamin the form customary in German-speaking countries. Both designate the same active substance (ATC N06BA12), a prodrug of dexamfetamine.
Why was lisdexamfetamine developed as a prodrug?
The binding to L-lysine delays and smooths the release of dexamfetamine and renders the molecule ineffective when snorted or injected. This lowers the abuse potential compared to immediate-release amphetamines and enables once-daily administration.
Does lisdexamfetamine cause dependence?
Lisdexamfetamine belongs to the class of stimulants with inherent dependence potential and is subject to the Controlled Substances Act. With correct indication and medically supervised use, the addiction risk for ADHD patients is low. Studies even show that treated ADHD patients have a lower risk of later substance abuse than untreated patients.
How do I know if the therapy is working?
Patients often report that they can concentrate better, are less distractible, complete tasks, and show reduced impulsive behavior. Objective progression assessment is performed using standardized ADHD scales (CAARS for adults, Conners for children), school or work performance, and feedback from the social environment.
Sources
- EMA, Elvanse (lisdexamfetamine) EPAR
- AWMF S3 guideline ADHD in children, adolescents, and adults
- Gelbe Liste, lisdexamfetamine active substance profile
- BfArM, Federal Institute for Drugs and Medical Devices
Legal Notices and Disclaimer
The information provided on this page is for general informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendation. It does not replace the advice of a licensed physician or pharmacist. Medications should only be taken as prescribed by a physician or dispensed by a pharmacy. All information is based on published product information and recognized scientific sources at the time of creation; the current product information from the manufacturer is always authoritative. Sanoliste assumes no liability for completeness, accuracy, or timeliness of the information presented. In a medical emergency, call emergency number 112.